Solvay submits cilansetron NDA

Solvay (Euronext:SOLB) submitted an NDA to FDA for cilansetron to treat irritable bowel syndrome with diarrhea predominance (IBS-D). In May, SOLB said cilansetron met the primary endpoint of adequate ...